/ /

  • linkedin
  • Increase Font
  • Sharebar

    Integrin peptide yields positive outcomes for VMA, VMT in phase II trial

    Dual mechanisms of action appear to inhibit new blood vessel formation, reduce leakage

    Take-home message: A new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.


    Orlando—A phase II clinical trial with the drug, ALG-1001 (Luminate, Allegro Ophthalmics), for vitreomacular traction (VMT) or vitreomacular adhesion (VMA) met its primary endpoint, according to study data.

    The trial evaluated the safety and efficacy of ALG-1001 intravitreal injections in 106 study subjects. The trial was prospective, double-masked, and placebo-controlled.

    The study divided 106 study subjects into three ALG-1001 groups (2.0 mg, 2.5 mg, and 3.2 mg) and a balanced salt solution placebo group. Sixty-five percent of eyes treated with the 3.2 mg dose of ALG-1001 had release of VMT or VMA by day 90, which was the end of the study, compared with 9.7% in the placebo control group.

    No drug toxicity or intraocular inflammation occurred.

    “These safety results are consistent with previously conducted [ALG-1001] studies on human subjects where there were no rod or cone photoreceptor dysfunction on full-field electroretinogram testing, no afferent pupillary defects, and no evidence of retinal tears or detachments,” according to a prepared statement.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results